Korean J Radiol.  2017 Feb;18(1):84-93. 10.3348/kjr.2017.18.1.84.

Update on Gastrointestinal Stromal Tumors for Radiologists

  • 1Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA. stirumani@partners.org
  • 2Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • 3Department of Radiology, Tata Memorial Centre, Mumbai 400012, India.
  • 4Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.


The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response to targeted therapies in GIST using conventional response criteria has several potential pitfalls leading to search for alternate response criteria based on changes in tumor attenuation, volume, metabolic and functional parameters. Surveillance of patients with GIST in the adjuvant setting is important for timely detection of recurrences.


Gastrointestinal stromal tumor; Imatinib; Risk stratification; Choi criteria

MeSH Terms

Antineoplastic Agents/therapeutic use
Benzamides/therapeutic use
Chemotherapy, Adjuvant
Combined Modality Therapy
Gastrointestinal Neoplasms/*diagnostic imaging/drug therapy/genetics
Gastrointestinal Stromal Tumors/*diagnostic imaging/drug therapy/genetics
Imatinib Mesylate/therapeutic use
Neoplasm Recurrence, Local
Pyrimidines/therapeutic use
Succinate Dehydrogenase/genetics
Tomography, X-Ray Computed
Antineoplastic Agents
Imatinib Mesylate
Succinate Dehydrogenase
Full Text Links
  • KJR
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr